Vanguard Global Advisers
ANIX icon

Vanguard Global Advisers’s Anixa Biosciences ANIX Stock Holding History

Vanguard Global Advisers’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Hold
10,729
– – ﹤0.01% 3225
2026
Q1 		$27.7K Buy
+10,729
New +$31.8K ﹤0.01% 3223

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vanguard Global Advisers's ANIX Position: Q2 2026 in Review

Vanguard Global Advisers held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 10,729 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #3225.

Vanguard Global Advisers first reported a position in ANIX in Q1 2026 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Vanguard Global Advisers held 10,729 shares of Anixa Biosciences worth $30K as of Q2 2026.
  • Vanguard Global Advisers left its Anixa Biosciences share count unchanged in Q2 2026.
  • Anixa Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3225 holding.
  • Vanguard Global Advisers first reported a position in Anixa Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.